Enliven Therapeutics (ELVN) Cash from Financing Activities (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Cash from Financing Activities data on file, last reported at $10.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 4196.15% year-over-year to $10.1 million; the trailing twelve-month figure through Mar 2026 stood at $228.7 million (up 430.24% YoY), and the FY2025 full-year result was $218.9 million, up 64.36% from the prior year.
• Cash from Financing Activities improved to $10.1 million in Q1 2026, from $623000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $237.4 million in Q1 2023 to a low of -$2.8 million in Q2 2023.
• A 5-year average of $35.0 million and a median of $409000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 57954.03% in 2023, while the deepest fall reached 56500.0% in 2023.
• Tracing ELVN's Cash from Financing Activities over 5 years: stood at -$2.4 million in 2022, then soared by 103.79% to $90000.0 in 2023, then jumped by 44313.33% to $40.0 million in 2024, then tumbled by 98.44% to $623000.0 in 2025, then soared by 1513.64% to $10.1 million in 2026.
• Business Quant data shows ELVN's Cash from Financing Activities at $10.1 million in Q1 2026, $623000.0 in Q4 2025, and -$368000.0 in Q3 2025.